Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Allopurinol Teva 100 mg tablets
Medicines register · Ireland

Allopurinol Teva 100 mg tablets

Authorisation PA0749/099/001 · Teva Pharma B.V.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Teva Pharma B.V. (all products →)
Active substance
Allopurinol
Clinical trials
6 clinical trials →
Dosage form
Tablet
Route of administration
Oral use
ATC codes
M04AA, M04AA01
First authorised
10/09/2010
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Allopurinol: supply and approvals

13 authorised products on the HPRA list contain Allopurinol. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
Allopurinol Tablet: resolved, updated 19 Feb 2026
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 16 years (since 10 September 2010). The HPRA list marks it as marketed in Ireland.

Other medicines with Allopurinol in Ireland

12 other products on the HPRA list contain Allopurinol, from 5 licence holders; 8 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Allopurinol 100 mg tabletsAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Allopurinol 300 mg tabletsAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Allopurinol Teva 300 mg tabletsTeva Pharma B.V.National authorisation (PA)Marketed
Alopur 100 mg tabletsRowex Limited,National authorisation (PA)Marketed
Alopur 300 mg tabletsRowex Limited,National authorisation (PA)Marketed
Tipuric 100 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Tipuric 300 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Zyloric 300 mg tabletsAspen Pharma Trading LimitedNational authorisation (PA)Marketed
Allopurinol Clonmel 100 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Not marketed
Allopurinol Clonmel 200 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Not marketed
Allopurinol Clonmel 300 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Not marketed
Zyloric 100 mg tabletsAspen Pharma Trading LimitedNational authorisation (PA)Not marketed

Other substances in ATC group M04AA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 1 other active substance shares the group M04AA with this product:

Febuxostat (10)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Teva Pharma B.V. holds 155 products on the HPRA list, with 69 different active substances; 100 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.